For decades, researchers have worked to develop therapies that can prime the immune system to recognize and attack proteins on the surface of tumor cells. However, success has been limited due to the ...
Please provide your email address to receive an email when new articles are posted on . Treatment induced sustained T-cell responses among patients with melanoma and non-small cell lung cancer. Phase ...
For decades, researchers have worked to develop therapies that can prime the immune system to recognize and attack proteins on the surface of tumor cells. However, success has been limited due to the ...
Considerations for neoantigen therapy tailored to specific patient needs is discussed by Dr Lipson. Discuss the 3-year updated data presented at ASCO 2024 on individualized neoantigen therapy ...
Cancer research today is rapidly evolving, exploring more modalities and personalized options to help patients. For many patients diagnosed with earlier stages of the disease, the potential for ...
-- Updated data from Phase 1/2 trial in end-stage metastatic MSS-CRC further support the association of circulating tumor DNA (ctDNA) reduction with extended overall survival -- -- GRANITE has ...
The Journal of Clinical Oncology Podcast presents analyses and discussions centered on the latest findings published in ASCO’s flagship Journal of Clinical Oncology. Host Dr. Davide Soldato ...
For decades, researchers have worked to develop therapies that can prime the immune system to recognize and attack proteins on the surface of tumor cells. However, success has been limited due to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results